Addario, B

Bittoni, M

Chen, R

Gitlitz, B

Jennings, M

Novello, Silvia

Oxnard, G.

Park, Sl

Sable Hunt, A

Vavala', Tiziana

English

Institutional Research Information System University of Turin

S174 Journal of Thoracic Oncology Vol. 11 No. 10SPD1.05 (also presented as P1.49)The Genomics of Young Emergent LungCancerBarbara Gitlitz,1 Bonnie Addario,2Alicia Sable-Hunt,3 Silvia Novello,4 Tiziana Vavala,4Ruthia Chen,5 Marisa Bittoni,6 S. Lani Park,1Mark Jennings,1 Geoffrey Oxnard5 1University ofSouthern California Keck School of Medicine, Los Angeles/CA/UNITED STATES OF AMERICA, 2Bonnie J. AddarioLung Cancer Foundation, San Carlos/CA/UNITED STATESOF AMERICA, 3Addario Lung Cancer Medical Institute, SanCarlos/CA/UNITED STATES OF AMERICA, 4University ofTurin, Turin/ITALY, 5Dana Farber Cancer Institute,Boston/MA/UNITED STATES OF AMERICA, 6Ohio StateUniversity, Columbus/OH/UNITED STATES OF AMERICABackground: Lung cancer is increasingly understood asa disease made up of genomically defined subtypesrequiring distinct treatment strategies. We hypothesizethat young age at diagnosis (< 40 years) is a clinicalcharacteristic associated with an increased chance for atargetable genomic alteration (GA). Our study will pro-spectively characterize the somatic and germline geno-mics of young lung cancer.Method: Accrual opened in July 2014. Patients (pts) areeligible if diagnosed with bronchogenic lung cancer <age40. The study website, allows for virtual consenting andremote participation from anywhere in the world. Wedefined 7 GA of interest based on the Lung Cancer Mu-tation Consortium (LCMC) (EGFR, KRAS, HER2, BRAF,ALK, ROS1, RET). We aim to show the prevalence oftargetable GA in our stage 4 adenocarcinoma (AC) ptswill be greater in our population compared to the LCMC,with an increase from 35% to 50%; and an improvementin use of targeted therapy from 22% to 40%. Studysubjects without a known genotype undergo genomicprofiling with the FoundationOne test.Results: Preliminary results of 71 pts with stage 4 ACshow that 82% have either an ALK re-arrangementn¼32 (45%), an EGFR activating mutation n¼17 (24%),a ROS1 fusion n¼5 (7%), a RET fusion n¼2 (3%) or aHER2 mutation n¼2 (3%). Other GA of interest in thosewith AC includes TP53, ATM and BRCA2 mutations. 49%of our accrual has come from web based consenting. Themajority of subjects have come from North America andEurope; and we would like representation from LatinAmerica.Conclusion: Thus far in our prospective series our re-sults have far exceeded our statistical expectations, with82% of our stage 4 AC pts having an actionable mutation.We have defined a genomically enriched subtype of lungcancer and laid the groundwork for further studies ofgermline and environmental lung cancer risk factors. Weare planning a large-scale Case Control study of theEpidemiology of YLC. Web based consenting is a feasiblemethod of bringing research to the patient.Keywords: Genomics, Young Emergent Lung Cancer,Remote ConsentingPD1.06 (also presented as P2.41)Pembrolizumab vs Docetaxel forPreviously Treated NSCLC(KEYNOTE-010): Archival vs NewTumor Samples for PD-L1 AssessmentRoy S. Herbst,1 Paul Baas,2 Jose L. Perez-Gracia,3Enriqueta Felip,4 Dong-Wan Kim,5 Ji-Youn Han,6Julian Molina,7 Joo-Hang Kim,8Catherine Dubos Arvis,9 Myung-Ju Ahn,10Margarita Majem,11 Mary Jo Fidler,12Veerle Surmont,13 Gilberto De Castro Jr.,14Marcelo Garrido,15 Yue Shentu,16Marisa Dolled-Filhart,16 Ellie Im,16Edward B. Garon17 1Yale School of Medicine, Yale CancerCenter, and Smilow Cancer Hospital, New Haven/CT/UNITED STATES OF AMERICA, 2The Netherlands CancerInstitute and The Academic Medical Hospital Amsterdam,Amsterdam/NETHERLANDS, 3Clinica Universidad deNavarra, Pamplona/SPAIN, 4Vall d’Hebron UniversityHospital and Vall d’Hebron Institute of Oncology,Barcelona/SPAIN, 5Seoul National University Hospital,Seoul/KOREA, REPUBLIC OF, 6National Cancer Center,Goyang/KOREA, REPUBLIC OF, 7Mayo Clinic, Rochester/MN/UNITED STATES OF AMERICA, 8CHA BundangMedical Center, CHA University, Gyeonggi-do/KOREA,REPUBLIC OF, 9Centre François Baclesse, Caen/FRANCE,10Samsung Medical Center Sungkyunkwan UniversitySchool of Medicine, Seoul/KOREA, REPUBLIC OF,11Hospital de la Santa Creu i Sant Pau, Barcelona/SPAIN,12Rush University Medical Center, Chicago/IL/UNITEDSTATES OF AMERICA, 13Universitair Ziekenhuis Ghent,Ghent/ BELGIUM, 14Instituto do Câncer do Estado de SãoPaulo, São Paulo/BRAZIL, 15Pontificia UniversidadCatólica de Chile, Santiago/CHILE, 16Merck & Co., Inc.,Kenilworth/NJ/ UNITED STATES OF AMERICA, 17DavidGeffen School of Medicine at the University of California,Los Angeles, Santa Monica/CA/UNITED STATES OFAMERICABackground: In KEYNOTE-010, pembrolizumab demo-nstrated superior OS over docetaxel in patients withPD-L1-expressing advanced NSCLC that progressed after2 cycles of platinum-doublet chemotherapy (HR 0.54,

PD1.05 (also presented as P1.49): The Genomics of Young Emergent Lung Cancer.

https://iris.unito.it/bitstream/2318/1622912/2/PD1.05%20%28also%20presented%20as%20P1.49%29_%20The%20Genomics%20of%20Young%20Emergent%20Lung%20Cancer.pdf

PD1.05 (also presented as P1.49): The Genomics of Young Emergent Lung Cancer.

Abstract

Similar works

Full text

Available Versions

Institutional Research Information System University of Turin